Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis

Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular... The purpose of this study was to evaluate the clinical efficacy, toxicity and adverse effects of stereotactic body radiotherapy (SBRT) combined with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). A total of 101 patients diagnosed with primary HCC with PVTT were enrolled in this study and were randomly divided into three groups as follows: group A, 34 patients treated with γ‑SBRT followed by TACE; group B, 37 patients treated with TACE followed by γ‑SBRT; and group C, 30 patients treated with γ‑SBRT alone. The effective response rate for the entire patient sample was 87.1% (88/101) following a 3‑month treatment. The differences in the response rate, survival rate, α‑fetoprotein level restoration rate and rate of improvement of abdominal distention and discomfort between groups A and B were not statistically significant (P>0.05). However, the rates of groups A and B were higher compared to those of group C (P<0.05). The exacerbation rate of liver function in group A was lower compared to that in group B (P<0.05), although it exhibited no statistically significant difference from that in group C (P>0.05). No severe radiation‑related complications were reported during the follow‑up period. The combination of γ‑SBRT and TACE was shown to be a relatively effective local treatment for primary HCC patients with PVTT. Compared to γ‑SBRT followed by TACE and γ‑SBRT alone, TACE followed by γ‑SBRT may exert a negative effect on liver function. These results suggested that the combination of TACE and γ‑SBRT may be considered a relatively effective, safe and feasible treatment method for primary HCC patients with PVTT, although TACE followed by γ‑SBRT may negatively affect liver function. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Molecular and Clinical Oncology Spandidos Publications

Stereotactic body radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis

Download PDF
8 pages

Loading next page...
 
/lp/spandidos-publications/stereotactic-body-radiotherapy-combined-with-transarterial-W54g6ZPw3e

References (27)

Publisher
Spandidos Publications
Copyright
Copyright © Spandidos Publications
ISSN
2049-9450
eISSN
2049-9469
DOI
10.3892/mco.2013.196
Publisher site
See Article on Publisher Site

Abstract

The purpose of this study was to evaluate the clinical efficacy, toxicity and adverse effects of stereotactic body radiotherapy (SBRT) combined with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). A total of 101 patients diagnosed with primary HCC with PVTT were enrolled in this study and were randomly divided into three groups as follows: group A, 34 patients treated with γ‑SBRT followed by TACE; group B, 37 patients treated with TACE followed by γ‑SBRT; and group C, 30 patients treated with γ‑SBRT alone. The effective response rate for the entire patient sample was 87.1% (88/101) following a 3‑month treatment. The differences in the response rate, survival rate, α‑fetoprotein level restoration rate and rate of improvement of abdominal distention and discomfort between groups A and B were not statistically significant (P>0.05). However, the rates of groups A and B were higher compared to those of group C (P<0.05). The exacerbation rate of liver function in group A was lower compared to that in group B (P<0.05), although it exhibited no statistically significant difference from that in group C (P>0.05). No severe radiation‑related complications were reported during the follow‑up period. The combination of γ‑SBRT and TACE was shown to be a relatively effective local treatment for primary HCC patients with PVTT. Compared to γ‑SBRT followed by TACE and γ‑SBRT alone, TACE followed by γ‑SBRT may exert a negative effect on liver function. These results suggested that the combination of TACE and γ‑SBRT may be considered a relatively effective, safe and feasible treatment method for primary HCC patients with PVTT, although TACE followed by γ‑SBRT may negatively affect liver function.

Journal

Molecular and Clinical Oncology – Spandidos Publications

Published: Jan 1, 2014

There are no references for this article.